

## PRISTINE BIOLOGICALS (NZ) LIMITED

*(A wholly owned subsidiary of Indian Immunologicals Limited)*

<b>Statement of Financial Performance</b> <b>For the year ended 31<sup>st</sup> March 2025</b>			
<b>S.No.</b>	<b>PARTICULARS</b>	<b>Year 2025</b> <b>(Amt in NZD)</b>	<b>Year 2024</b> <b>(Amt in NZD)</b>
1.	Total Sales	53,97,382	37,35,763
2.	Cost of sales	31,66,274	18,72,005
	<b>Gross Surplus</b>	<b>22,31,108</b>	<b>18,63,758</b>
4.	Add: Other Income	14	20
5.	Less: Expenses	10,34,767	8,47,679
	<b>Net surplus/(deficit) before depreciation</b>	<b>11,97,905</b>	<b>10,16,420</b>
6.	Less : Other adjustments (Depreciation/Foreign currency loss/other Taxation)	3,38,861	2,86,406
	<b>NET SURPLUS/(DEFICIT)</b>	<b>8,59,044</b>	<b>7,30,014</b>

<b>Statement of Financial Position as at 31<sup>st</sup> March 2025</b>			
<b>S.No.</b>	<b>PARTICULARS</b>	<b>Year 2025</b> <b>(Amt in NZD)</b>	<b>Year 2024</b> <b>(Amt in NZD)</b>
1.	Current Assets	28,97,768	19,89,285
2.	Non-Current Assets	17,14,466	17,71,023
	<b>TOTAL ASSETS</b>	<b>46,12,235</b>	<b>37,60,307</b>
3.	Current Liabilities	8,00,409	7,18,162
4.	Non-Current Liabilities	4,02,133	4,91,496
	<b>TOTAL LIABILITIES</b>	<b>12,02,542</b>	<b>12,09,658</b>
	<b>NET ASSETS</b>	<b>34,09,693</b>	<b>25,50,649</b>
	<b>TOTAL EQUITY</b>	<b>34,09,693</b>	<b>25,50,649</b>